Drugs Made In America Acquisition Corp. (DMAA)
NASDAQ: DMAA · Real-Time Price · USD
10.59
0.00 (-0.05%)
May 15, 2026, 10:14 AM EDT - Market open
Company Description
Drugs Made In America Acquisition Corp. does not have significant operations.
It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses.
Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Drugs Made In America Acquisition Corp.
| Country | United States |
| Founded | 2024 |
| IPO Date | Jan 28, 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Roger Bendelac |
Contact Details
Address: 420 Lexington Avenue, Suite 1402 New York, New York 10170 United States | |
| Phone | 646 726 7074 |
Stock Details
| Ticker Symbol | DMAA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 2028614 |
| ISIN Number | KYG2847J1040 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Roger Bendelac | Chief Executive Officer |
| Saleem Elmasri CPA | Chief Financial Officer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | SCHEDULE 13G | Filing |
| May 5, 2026 | 425 | Filing |
| May 5, 2026 | 8-K | Current Report |
| May 1, 2026 | 8-K | Current Report |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 16, 2026 | DEFR14A | Filing |
| Apr 15, 2026 | 10-K | Annual Report |
| Apr 14, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2026 | 8-K | Current Report |